BACKGROUND: Diabetic retinopathy in Alberta and throughout Canada is common, with a prevalence up to 40% in people with diabetes. Unfortunately, due to travel distance, time, and expense, a third of patients with diabetes do not receive annual dilated eye examinations by ophthalmologists, despite universal health care access. In an effort to improve access, a teleophthalmology program was developed to overcome barriers to eye care. Prior to clinical implementation, teleophthalmology technology was clinically validated for the identification of treatable levels of diabetic retinopathy. METHOD: Patients undergoing a teleophthalmology assessment underwent stereoscopic digital retinal photographs following pupillary dilation. Digital images were then packaged into an encrypted password-protected compressed file for uploading onto a secure server. Images were digitally unpackaged for review as a stereoscopic digital slide show and graded with a modified Early Treatment Diabetic Retinopathy Study algorithm. Reports were then generated automatically as a PDF file and sent back to the referring physician. RESULTS: Teleophthalmology programs in Alberta have assessed more than 5500 patients (9016 visits) to date. Nine hundred thirty patients have been referred for additional testing or treatment. Approximately 2% of teleophthalmology assessments have required referral for in-person examination due to ungradable image sets, most commonly due to cataract, corneal drying, or asteroid hyalosis. CONCLUSIONS: In Alberta and throughout Canada, many patients with diabetes do not receive an annual dilated eye examination. Teleophthalmology is beneficial because patients can be assessed within their own communities. This decreases the time to treatment, allows treated patients to be followed remotely, and prevents unnecessary referrals. Health care costs may be reduced by the introduction of comprehensive teleophthalmology examinations by enabling testing and treatment to be planned prior to the patient's first visit. (c) 2009 Diabetes Technology Society.
BACKGROUND:Diabetic retinopathy in Alberta and throughout Canada is common, with a prevalence up to 40% in people with diabetes. Unfortunately, due to travel distance, time, and expense, a third of patients with diabetes do not receive annual dilated eye examinations by ophthalmologists, despite universal health care access. In an effort to improve access, a teleophthalmology program was developed to overcome barriers to eye care. Prior to clinical implementation, teleophthalmology technology was clinically validated for the identification of treatable levels of diabetic retinopathy. METHOD:Patients undergoing a teleophthalmology assessment underwent stereoscopic digital retinal photographs following pupillary dilation. Digital images were then packaged into an encrypted password-protected compressed file for uploading onto a secure server. Images were digitally unpackaged for review as a stereoscopic digital slide show and graded with a modified Early Treatment Diabetic Retinopathy Study algorithm. Reports were then generated automatically as a PDF file and sent back to the referring physician. RESULTS: Teleophthalmology programs in Alberta have assessed more than 5500 patients (9016 visits) to date. Nine hundred thirty patients have been referred for additional testing or treatment. Approximately 2% of teleophthalmology assessments have required referral for in-person examination due to ungradable image sets, most commonly due to cataract, corneal drying, or asteroid hyalosis. CONCLUSIONS: In Alberta and throughout Canada, many patients with diabetes do not receive an annual dilated eye examination. Teleophthalmology is beneficial because patients can be assessed within their own communities. This decreases the time to treatment, allows treated patients to be followed remotely, and prevents unnecessary referrals. Health care costs may be reduced by the introduction of comprehensive teleophthalmology examinations by enabling testing and treatment to be planned prior to the patient's first visit. (c) 2009 Diabetes Technology Society.
Authors: Christopher J Rudnisky; Brad J Hinz; Matthew T S Tennant; Alexander R de Leon; Mark D J Greve Journal: Ophthalmology Date: 2002-02 Impact factor: 12.079
Authors: P Massin; J P Aubert; E Eschwege; A Erginay; J C Bourovitch; A BenMehidi; M Nougarède; S Bouée; F Fagnani; M S Tcherny; M Jamet; M Bouhassira; M Marre Journal: Diabetes Metab Date: 2005-04 Impact factor: 6.041
Authors: Jerry Cavallerano; Mary G Lawrence; Ingrid Zimmer-Galler; Wendell Bauman; Sven Bursell; W Kelley Gardner; Mark Horton; Lloyd Hildebrand; Jay Federman; Lisa Carnahan; Peter Kuzmak; John M Peters; Adam Darkins; Jehanara Ahmed; Lloyd M Aiello; Lloyd P Aiello; Gary Buck; Ying Ling Cheng; Denise Cunningham; Eric Goodall; Ned Hope; Eugene Huang; Larry Hubbard; Mark Janczewski; J W L Lewis; Hiro Matsuzaki; Francis L McVeigh; Jordana Motzno; Diane Parker-Taillon; Robert Read; Peter Soliz; Bernard Szirth; Robert A Vigersky; Thomas Ward Journal: Telemed J E Health Date: 2004 Impact factor: 3.536
Authors: Taras V Litvin; Glen Y Ozawa; George H Bresnick; Jorge A Cuadros; Matthew S Muller; Ann E Elsner; Thomas J Gast Journal: Optom Vis Sci Date: 2014-04 Impact factor: 1.973
Authors: Joshua D Stein; Kapil G Kapoor; Joshua L Tootoo; Ruiyang Li; Alan Wagner; Chris Andrews; Marie Lynn Miranda Journal: JAMA Ophthalmol Date: 2018-01-01 Impact factor: 7.389
Authors: David T Liss; Jessica Chubak; Melissa L Anderson; Kathleen W Saunders; Leah Tuzzio; Robert J Reid Journal: Ann Fam Med Date: 2011 Jul-Aug Impact factor: 5.166
Authors: Rolake O Alabi; Amy Ansin; Jameson Clover; John Wilkins; Naveen K Rao; Mark A Terry; Khoa D Tran; Christopher S Sales Journal: Cornea Date: 2019-04 Impact factor: 2.651
Authors: Jennifer Threatt; Jennifer F Williamson; Kyle Huynh; Richard M Davis; Kathie Hermayer Journal: Am J Med Sci Date: 2013-04 Impact factor: 2.378